Baird Maintains Outperform on Editas Medicine, Raises Price Target to $6
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Baird analyst Joel Beatty maintains Editas Medicine (NASDAQ:EDIT) with a Outperform and raises the price target from $4 to $6.
Baird analyst Joel Beatty maintains Editas Medicine (NASDAQ:EDIT) with a Outperform and raises the price target from $4 to $6.